On November 4th (EST), phase II clinical data in IgA Nephropathy of Telitacicept was presented as Late-Breaking poster at the Annual meeting of the American Society of Nephrology. Telitacicept, researched and developed by Remegen, , the first dual-targeting biologics approved to treat systemic lupus erythematosus (SLE) globally, once again demonstrates promising data in a new indication.
IgA Nephropathy is one of the most common primary glomerulonephritis, accounting for about 25%-50% of primary glomerulonephritis in China, of which 25%-30% will develop end-stage renal disease (ESRD) within 20 years. According to Frost & Sullivan, the total number of IgA nephropathy patients is expected to reach 10.2 million globally and 2.4 million in China by 2030.
At present, Telitacicept is the only original novel biologics in clinical research in China, and the phase Ⅲ clinical trial will be initiated soon. As the first BLyS/APRIL dual-targeting fusion protein novel biologics globally, Telitacicept combines BLyS and APRIL, two important factors affecting the survival and activity of B-cells, and inhibits the proliferation and maturation of B-cells and antibody secretion, which is expected to become a new choice for IgA nephropathy treatment and open a new era of targeted therapy with biological agents. Before this, the IgA nephropathy indication of Telitacicept have been granted approval by FDA, phase Ⅱ clinical trial is on-going in the United States.
